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Objective. We sought to assess the risk of major adverse cardiovascular events (MACE) by 
utilizing high-sensitivity C-reactive protein (hsCRP) level and low-density lipoprotein 
cholesterol (LDL-C) in patients with type 2 diabetes and recent acute coronary syndrome.  
Research Design and Methods. Study participants enrolled in the EXAMINE trial, were 
stratified by baseline hsCRP levels (<1, 13, and >3 mg/l) and were also sub-divided into 4 
groups according to baseline hsCRP (3 or >3 mg/l) and achieved LDL-C (<70 or 70 mg/dl) 
levels. Among 5,380 patients, the MACE rate, a composite of cardiovascular death, non-fatal 
acute myocardial infarction, and non-fatal stroke, was evaluated during the 30 months of 
follow-up. 
Results. Cumulative incidence of MACE was 11.5% (119 events), 14.6% (209 events), and 
18.4% (287 events) in patients with hsCRP levels of <1, 13, and >3 mg/l, respectively 
(P<0.001). In patients with hsCRP >3 mg/l, the adjusted hazard ratio (95% confidence 
interval) was 1.42 (1.13, 1.78; P=0.002) for MACE compared with patients with hsCRP <1 
mg/l. MACE cumulative incidences were 11.0% (128 events), 14.4% (100 events), 15.6% 
(194 events), and 21.3% (182 events) in patients with low LDL-C and low hsCRP, low LDL-
C and high hsCRP, high LDL-C and low hsCRP, and high LDL-C and high hsCRP levels, 
respectively (P<0.001). 
Conclusions. Levels of hsCRP were associated with recurrent cardiovascular events in 
patients with type 2 diabetes and recent acute coronary syndrome, and this association 
appears to be independent of and additive to the achieved LDL-C level. 
 
Clinical trials registration number:  NCT00968708 
 
 
Introduction 
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Inflammation plays a key role in the pathogenesis of atherosclerosis (1). There are numerous 
diverse markers for systemic inflammation, but among them, high-sensitivity C-reactive 
protein (hsCRP) is one of the best studied biomarkers for vascular risk in both primary and 
secondary prevention settings (2, 3). In primary prevention, cardiovascular risk predictions 
according to CRP concentration are comparable to those according to systolic blood pressure, 
total cholesterol, and non-high-density lipoprotein (HDL) cholesterol levels (4). In a meta-
analysis addressing secondary prevention, hsCRP concentrations measured within 72 hours 
from the onset of acute coronary syndrome were associated with a higher long-term risk of 
recurrent cardiovascular events (5).  However, because hsCRP rises 5-8 times in the setting 
of ACS, the cutpoints used in the acute setting differ from a stable population.  
To date, several prospective studies have examined the role of hsCRP in predicting 
future CV morbidity and mortality in stable patients with type 2 diabetes mellitus with 
varying results (6-12). The aim of our study was to determine whether the baseline hsCRP 
level is predictive of the risk of major adverse cardiovascular events (MACE), a composite of 
cardiovascular death, non-fatal myocardial infarction, and stroke, in high CV risk patients 
with type 2 diabetes and a recent acute coronary syndrome (ACS) enrolled in the 
Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care 
(EXAMINE) trial (13). In addition, we evaluated whether the associations between the 
hsCRP level and future CV outcomes were independent of achieved low-density lipoprotein 
(LDL) cholesterol levels. 
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Methods 
Study design and patients 
The design of the EXAMINE study has been published previously (13). EXAMINE was a 
multicenter, randomized, double-blind study that evaluated the efficacy and safety of the 
dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin in 5,380 patients diagnosed with type 2 
diabetes and an acute coronary syndrome within 15 to 90 days before randomization. Other 
inclusion criteria required a glycated hemoglobin level of 6.5%11.0% at baseline or, if the 
antidiabetic regimen included insulin, a glycated hemoglobin level of 7.0%10.0%. Major 
exclusion criteria were a diagnosis of type 1 diabetes; unstable cardiac disorders including 
New York Heart Association Functional Classification IV heart failure, refractory angina, 
uncontrolled arrhythmia, critical valvular heart disease, or severe uncontrolled hypertension; 
and dialysis within 14 days before screening. 
 Patients were randomly assigned to receive alogliptin or placebo, administered in a 
double-blind fashion, in addition to standard-of-care treatment for type 2 diabetes. 
Throughout the study, patients were required to receive standard-of-care treatment for type 2 
diabetes and cardiovascular risk factors according to regional guidelines. Because alogliptin 
is cleared by the kidney, alogliptin and matching placebo doses were modified according to 
the estimated glomerular filtration rate (GFR, MDRD) at baseline and after randomization. 
 
Cardiovascular adjudication 
The composite MACE endpoint consisted of cardiovascular death, non-fatal acute myocardial 
infarction, and non-fatal stroke. Cardiovascular death was defined as death from cardiac and 
cerebrovascular causes, and any death without another known cause. Urgent revascularization 
due to unstable angina, hospitalization for heart failure, and death from any cause also were 
adjudicated. Cardiovascular events and all deaths were adjudicated by members of an 
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independent cardiovascular endpoints committee who were blinded to treatment assignment 
(Cleveland Clinic Cardiovascular Endpoint Committee, Cleveland, OH). 
Measurement of hsCRP 
Venous blood samples were obtained in EDTA-treated tubes at study entry as part of the 
study protocol. Plasma samples were transported refrigerated overnight to the central 
laboratory, and stored at -80ºC or colder until analyzed after a single freeze-thaw cycle. The 
hsCRP was measured at baseline in all available samples (n = 5,380) using a validated latex-
enhanced turbidimetric immunoassay (Hitachi 747 analyzer). All assays were performed by 
laboratory personnel blinded to treatment allocation and clinical outcome. 
Statistical analysis 
Study participants were stratified by baseline hsCRP values using established decision limits 
(<1, 1-3, and >3 mg/l) for prediction of cardiovascular outcomes (3). Data are expressed as 
mean ± SD or median and interquartile range for continuous measures, or as proportions for 
categorical variables. Differences between groups were tested by ANOVA or Wilcoxon rank-
sum test for continuous variables and the Ȥ2-test or Fishers exact test for categorical variables. 
Event rates through 30 months were calculated using the Kaplan-Meier method. Multivariate 
Cox proportional hazards models were used to analyze the time to the occurrence of CV 
outcomes in association with baseline hsCRP levels. The covariates included in the adjusted 
model were treatment group, age, sex, body mass index, current smoking, total cholesterol, 
estimated GFR, blood pressure, glycated hemoglobin, and duration of diabetes. Assessment 
of the treatment effect of alogliptin was performed on an intention-to-treat basis. To 
determine potential shared effects, study participants were divided into 4 groups according to 
both baseline hsCRP (3 or >3 mg/l) and achieved LDL-C (<70 or 70 mg/dl). With this 
combination, we determined whether the hsCRP level has an independent and additional role 
to assess cardiovascular risk beyond that conveyed by the achieved LDL-C level, as defined 
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by current guidelines (14, 15). A two-sided p-value of 0.05 was considered significant for all 
tests. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and were 
performed by the biometrics group at the Baim Clinical Research Institute (Boston, MA). 
Results 
The baseline characteristics of study participants according to baseline hsCRP concentrations 
(<1, 1-3, and >3 mg/l) are shown in Table 1. Of the 5,380 subjects who had an hsCRP 
concentration measured at baseline, approximately 40% (n=2,139) had an hsCRP 
concentration of >3 mg/l. Patients with higher hsCRP levels (>3 mg/l) were more obese, and 
more likely to have higher blood pressure; higher fasting glucose, glycated hemoglobin, 
LDL-C, and triglyceride levels; and lower HDL cholesterol levels than patients with average 
to lower hsCRP levels (3 mg/l). The high hsCRP patients were also more likely to be current 
smokers and have a history of hypertension, coronary bypass surgery, congestive heart failure, 
or peripheral artery disease and were less likely to have a history of percutaneous coronary 
intervention. 
During a median duration of 18 months of follow-up, cumulative incidences of 
MACE were 11.5% (119 events), 14.6% (209 events), and 18.4% (287 events) in patients 
with baseline hsCRP <1, 1-3, and >3 mg/l, respectively (P<0.001) (Figure 1). Similarly, 
cumulative incidences of hospitalization for heart failure or death from any cause were 
related to both baseline hsCRP and achieved LDL-C levels (both P<0.001). No differences in 
the rates of urgent revascularization for unstable angina were observed across the hsCRP 
concentrations (Supplemental Figure 1). 
In patients with baseline hsCRP >3 mg/l, the adjusted hazard ratio (HR) (95% 
confidence interval [CI]) was 1.42 (95% CI, 1.13, 1.78; P=0.002) for MACE, 1.40 (1.04, 1.89; 
P=0.025) for non-fatal myocardial infarction, 2.04 (1.34, 3.11; P<0.001) for hospitalization 
for heart failure, and 1.77 (1.29, 2.42; P<0.001) for death from any cause, compared to 
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patients with baseline hsCRP <1 mg/l, and were independent of treatment group, age, sex, 
body mass index, current smoking, total cholesterol, estimated GFR, blood pressure, glycated 
hemoglobin, and duration of diabetes. Baseline hsCRP concentrations did not show an 
independent association with the individual endpoints of death from cardiovascular causes, 
non-fatal stroke, or urgent revascularization due to unstable angina. In addition, patients with 
average concentrations of hsCRP (13 mg/l) had a CV risk comparable to patients with lower 
baseline hsCRP concentrations (<1 mg/l) (Table 2). 
Results for the groups evaluated according to both baseline hsCRP (3 or >3 mg/l) 
and achieved LDL-C (<70 or >70 mg/dl) a) are shown in Figure 2. Cumulative incidences of 
MACE were 11.0% (128 events), 14.4% (100 events), 15.6% (194 events), and 21.3% (182 
events) in patients with low LDL-C and low hsCRP concentrations, low LDL-C and high 
hsCRP concentrations, high LDL-C and low hsCRP concentrations, and high LDL-C and 
high hsCRP concentrations, respectively (P<0.001). Hospitalization for heart failure and 
death from any cause were also related to both baseline hsCRP and achieved LDL-C levels 
(both P<0.001). Cumulative incidences of urgent revascularization for unstable angina were 
similar among the 4 groups (Supplemental Figure 2). 
 
Discussion 
In patients with type 2 diabetes and a recent acute coronary syndrome we have determined 
that baseline hsCRP levels are predictive for developing recurrent MACE. Patients with a 
higher baseline hsCRP level (>3 mg/l) developed cardiovascular events regardless of the 
achieved LDL-C level and this association persisted even in patients with an achieved LDL-C 
level of <70 mg/dl, a threshold value recommended by most current guidelines for patients 
with coronary disease (14, 15). Incorporating both hsCRP and LDL-C provided additional 
stratification of risk, with a more than 2 fold higher risk when both markers were elevated. 
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The patterns are similar to those seen in other patient populations who did not have type 2 
diabetes, or a recent ACS. As such, use of these two simple and widely available tests could 
help to risk stratify this group of patients.  
It has been suggested that the association between hsCRP level and CV disease risk 
is generally weaker in patients with type 2 diabetes compared with those without diabetes 
(16-18). Type 2 diabetes is characterized by diverse CV risk factors including high 
triglycerides and low HDL cholesterol levels, hypertension, and hyperglycemia per se, and 
these multiple risk factors may partially mask the role of hsCRP as a risk factor for CV 
morbidity and mortality (16-18). In an analysis from the Collaborative Atorvastatin Diabetes 
Study (CARDS) trial, the baseline CRP level was not predictive of future CV disease. 
Moreover, the efficacy of statins was not different according to achieved CRP levels, and thus, 
the authors did not support the use of CRP as an indicator for statin efficacy in patients with 
type 2 diabetes (10). Collectively, these data suggested that in populations with increased 
inflammatory and vascular burden, the measurement of hsCRP may have limited clinical 
relevance in the assessment of the future development of CV events. 
In contrast, several prospective cohort studies have shown that individuals with 
higher CRP levels were at risk for future CV disease, including patients with type 2 diabetes 
(6-9). In a population-based Italian cohort followed up for 5 years, higher CRP values (>3 
mg/l) were associated with increased overall and cardiovascular mortality in patients with 
type 2 diabetes after adjusting for conventional CV risk factors (6). Similarly, in a study 
performed with 878 Finnish subjects with type 2 diabetes who were free of myocardial 
infarction at baseline, coronary heart disease mortality was increased in subjects with a higher 
CRP level (>3 mg/l) (7). Therefore, there is still equipoise regarding the usefulness of 
measuring the hsCRP level to assess CV risk in patients with a high vascular risk, including 
those with type 2 diabetes and previous CV disease from the ADVANCE study (11) and those 
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with acute coronary syndromes (12).  
While some of the above-referenced results are discrepant with those from 
EXAMINE, there are substantial differences in the patient populations. Our study was 
comprised of patients with an acute coronary syndrome on average 45 days before 
randomization, and most patients (>90%) were already receiving a statin at baseline; in 
ADVANCE, only one-third (34.8%) of patients had a history of previous CV disease and 
fewer patients had had statin treatment at baseline. Of note, in the 1,345 patients (34.8%) who 
had a history of CV disease at baseline in ADVANCE (11), the hsCRP level was not 
associated with recurrent vascular events [HR (95% CI), 1.09 (0.96, 1.23)] (11).  
In addition, subjects from the ADVANCE trial had a median hsCRP level of 1.8 mg/l 
at baseline. Despite the well-known reduction in hsCRP after treatment with statins, the 
EXAMINE patients had a higher on-treatment median hsCRP level of 2.2 mg/l. Therefore, 
EXAMINE patients may have had a greater inflammatory burden than those in other study 
populations, that cannot be entirely captured by CV risk factors driven by type 2 diabetes and 
a history of cardiovascular disease. Our findings demonstrate that a higher hsCRP value can 
predict future secondary CV events in patients with established CV disease. In support of this 
notion is the finding that there was a graded increase in future CV risk across a full range of 
hsCRP values and risk scores from the Framingham study (19). 
Another key finding of our analysis is that the hsCRP value was independent of, and 
additive to, the achieved LDL-C level in predicting future CV events. There has been 
controversy regarding whether there are non-lipid lowering pleomorphic benefits of statins. A 
meta-regression analysis showed a strong correlation between LDL-C reduction and hsCRP 
reduction (r=0.80, P<0.001), and at least 90% of the hsCRP reduction with lipid-lowering 
drugs may be explained by the reduction in LDL-C (20). This would lead to the conclusion 
that the potential non-lipid-lowering effects of statins on inflammation might be modest in 
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magnitude. In contrast, results from a secondary analysis from the JUPITER trial 
demonstrated that the correlation between the reduction in hsCRP and the reduction in LDL-
C was relatively weak (r=0.15) and relative risk for vascular events with rosuvastatin, 20 mg 
daily, was 0.45 in those who achieved an LDL-C level of <70 mg/dl, 0.38 in those who 
achieved an hsCRP level of <2.0 mg/l, and 0.35 in those who achieved both LDL-C and 
hsCRP targets together. Thus, the authors concluded that not only LDL-C reduction, but also 
hsCRP reduction, could be induced by statin therapy (21). Finally, the PROVE IT-TIMI 22 
trial demonstrated that hsCRP reduction is beneficial for preventing vascular events whether 
or not LDL-C levels were reduced to target value of <70 mg/dl with statin treatment (22). 
In EXAMINE, the cumulative incidences of MACE, hospitalization for heart failure, 
and death from any cause were the lowest in patients achieving both an LDL-C <70 mg/dl 
and hsCRP <3.0 mg/l. However, there were mismatches in the LDL-C levels and hsCRP in 
EXAMINE. For example, low LDL-C (<70 mg/dl) but high hsCRP (>3.0 mg/l) values with 
statin treatment were observed in 47.1% (2,503/5,310) of the study patients. In addition, one-
third of our patients (33.4%, 882/2,640) had an hsCRP level of >3.0 mg/l despite achieving 
an LDL-C target of <70 mg/dl. This suggests that both the achieved LDL-C and the hsCRP 
levels had independent as well as additive effects in predicting future CV risk, and support 
the non-lipid lowering benefits of statins, such as its anti-inflammatory properties. 
Our analysis has some limitations. We only had a single measurement of hsCRP at 
the baseline period, and therefore, we cannot exclude the possibility of some variability in the 
hsCRP level from an acute-phase reaction. However, a non-CV inflammatory condition 
causing an hsCRP elevation is more likely to underestimate the true association between 
hsCRP value and CV outcomes and not falsely overestimate the risk relationship. We also did 
not have information regarding other risk factors possibly affecting future cardiovascular 
disease including socioeconomic status, physical activity, dietary factors, and family history 
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of cardiovascular disease. 
In conclusion, in patients with type 2 diabetes and high cardiovascular risk, with a 
recent acute coronary syndrome but well treated with statins and with good glycemic control, 
we have found a significant association between on-treatment hsCRP values and future CV 
outcomes. The results indicate that patients achieving goal LDL-C targets of <70 mg/dl with 
statin therapy, may benefit from the measurement of both hsCRP and LDL-C to assess 
residual cardiovascular risk. 
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Figure 1. Time to the primary endpoint (major adverse cardiovascular events) 
according to baseline high-sensitivity C-reactive protein (hs-CRP) in the 
EXAMINE trial. 
 
Figure 2.  Time to the primary endpoint (major adverse cardiovascular events) 
according to baseline high-sensitivity C-reactive protein (hs-CRP) and low 
density lipoprotein (LDL) cholesterol in the EXAMINE trial. 
. 
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le Table 1 Baseline characteristics according to high-sensitivity C-reactive protein concentrations 
 High-sensitivity C-reactive protein stratification P-value 
<1 mg/dl (n=1,278) 1-3 mg/dl (n=1,963) >3 mg/dl (n=2,139) 
High-sensitivity C-reactive protein 
(mg/l) 
0.6 (0.40.8) 1.7 (1.32.3) 6.2 (4.211.9) <0.001 
Age (years) 61.4 (9.7) 60.9 (10.0) 60.5 (10.0) 0.022 
Male (%) 75.7 (968) 68.0 (1334) 63.1 (1349) <0.001 
Body mass index (kg/m2) 27.3 (4.5) 29.3 (5.0) 30.9 (6.2) <0.001 
Cardiovascular risk factors and 
history (%) 
    
Current smoker 11.0 (141) 12.2 (239) 16.5 (354) <0.001 
Hypertension 78.5 (1003) 82.9 (1628) 85.9 (1838) <0.001 
Dyslipidemia 28.1 (359) 27.7 (543) 25.7 (550) 0.22 
Myocardial infarction 87.6 (1119) 88.1 (1729) 88.2 (1886) 0.86 
Coronary bypass surgery 9.2 (118) 12.2 (240) 15.4 (330) <0.001 
Percutaneous coronary 67.0 (856) 61.7 (1211) 61.0 (1305) 0.001 
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Congestive heart failure 22.8 (292) 27.0 (530) 31.7 (679) <0.001 
Transient ischemic attack 1.8 (23) 2.8 (54) 3.2 (68) 0.054 
Peripheral arterial disease 6.8 (87) 9.6 (188) 11.2 (239) <0.001 
Systolic blood pressure (mmHg) 127.8 (16.9) 129.1 (16.2) 129.5 (16.8) 0.014 
Diastolic blood pressure (mmHg) 75.5 (9.9) 76.5 (9.3) 76.8 (9.9) <0.001 
Glycated hemoglobin (%) 7.9 (1.1) 8.0 (1.1) 8.1 (1.1) <0.001 
Fasting glucose (mg/dl) 140.0 (116.0173.0) 146.0 (121.0185.0) 148.0 (122.0189.0) <0.001 
Total cholesterol (mg/dl) 139.0 (119.0166.0) 148.0 (125.0178.0) 151.0 (126.0184.0) <0.001 
HDL cholesterol (mg/dl) 43.0 (37.051.0) 42.0 (36.049.0) 41.0 (35.048.0) <0.001 
LDL-C (mg/dl) 67.0 (50.088.0) 72.0 (55.097.0) 76.0 (57.0102.0) <0.001 
Triglyceride (mg/dl) 127.0 (93.0171.0) 145.0 (107.0200.0) 146.0 (106.0205.0) <0.001 
Estimated GFR (ml/min/1.73 m2) 71.7 (20.4) 71.9 (21.2) 69.6 (22.1) <0.001 
Index ACS (%)     
Myocardial infarction 78.6 (1003) 76.3 (1494) 77.6 (1655) 0.31 
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Time between index ACS and 
randomization (days) 
48.0 (32.067.0) 44.0 (30.064.0) 43.0 (28.062.0) <0.001 
Data are expressed as percentage (number), mean (SD), or median (interquartile range). 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; GFR, glomerular filtration rate; ACS, acute coronary syndrome 
LDL-C levels were measured in 1,271, 1,928, and 2,111 patients, and index ACS cases were determined in 1,276, 1,957, and 2,133 in patients, 
with hsCRP levels of <1, 1-3, and >3 mg/l, respectively. In addition, body mass index was determined in 1,277 patients with hsCRP levels of 
<1 mg/l, and HDL cholesterol was measured in 1,962 patients with hsCRP levels of 1-3 mg/l. 
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 High-sensitivity C-reactive protein stratification P-value 
<1 mg/dl (n=1,278) 1-3 mg/dl (n=1,963) >3 mg/dl (n=2,139) 
Major adverse cardiovascular events Reference 1.11 (0.88, 1.40) 1.42 (1.13, 1.78) 0.002 
Death from cardiovascular causes  0.97 (0.67, 1.40) 1.40 (0.98, 2.00) 0.06 
Non-fatal myocardial infarction  1.14 (0.85, 1.54) 1.40 (1.04, 1.89) 0.025 
Non-fatal stoke  1.62 (0.81, 3.22) 1.57 (0.79, 3.13) 0.20 
Urgent revascularization due to unstable 
angina 
 1.22 (0.72, 2.08) 0.91 (0.52, 1.61) 0.75 
Hospitalization for heart failure  1.30 (0.83, 2.04) 2.04 (1.34, 3.11) <0.001 
Death from any cause  1.12 (0.80, 1.55) 1.77 (1.29, 2.42) <0.001 
Data are expressed as hazard ratio (95% confidence interval). 
Data were adjusted for treatment group, age, sex, body mass index, current smoking, total cholesterol, estimated glomerular filtration rate, 
systolic blood pressure, diastolic blood pressure, glycated hemoglobin, and diabetes duration. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le  
 
 
 
 
 
This article is protected by copyright. All rights reserved.
